Zuellig Pharma, a major healthcare solutions provider in Asia, has announced that it has acquired the rights to Cialis® (Tadalafil) from Eli Lilly and Company in Hong Kong, Macau, and South Korea.
With this deal, Zuellig Pharma now owns the trademarks, marketing approvals, and manufacturing knowledge for Cialis® in 11 markets across Asia, expanding its ownership to three more markets beyond the original eight.
Cialis® is a medicine used to treat erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). Zuellig Pharma will also continue to promote and distribute the product in these markets.
The expanded ownership of Cialis® will help make the medicine more accessible to many men across Asia who suffer from erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). The acquisition also supports Zuellig Pharma’s strategy to strengthen its portfolio of owned prescription healthcare products as it continues to grow as an integrated healthcare solutions provider.
“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Zuellig Pharma is a leading healthcare solutions company in Asia with a mission to make healthcare more accessible for communities. The company offers services such as distribution, commercialization, and clinical trial support, backed by a strong focus on innovation to meet the region’s growing healthcare needs.
Founded more than 100 years ago, Zuellig Pharma has grown into a multibillion-dollar business operating in 18 markets with over 12,000 employees. Its team supports more than 200,000 medical facilities and works with over 450 clients, including many of the world’s top pharmaceutical companies.
Read More- Shorooq Invests in Yann LeCun’s AI Startup AMI Labs in $1.03B Funding Round
